Effect of EARLY administration of DEXamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome (EARLY-DEX COVID-19): study protocol for a randomized controlled trial.

Anabel Franco-MorenoMaría Soledad Acedo-GutiérrezNicolás Labrador-San MartínClara Hernández-BlancoCelia Rodríguez-OllerosFátima Ibáñez-EstéllezAna Suárez-SimónMateo Balado-RicoAna Rocío Romero-PaterninaDavid Alonso-MenchénBelén Escolano-FernándezEsther Piniella-RuizEster Alonso-MongeHelena Notario-LeoCarlos Bibiano-GuillénGabriela Peña-LilloArmando Antiqueira-PérezRodolfo Romero-ParejaNoemí Cabello-ClotetVicente Estrada-PérezJesús Troya-GarcíaMaría de Carranza-LópezIsmael Escobar-RodríguezNacho Vallejo-MarotoJuan Torres-Macho

Published in: Trials (2022)

ClinicalTrials.gov NCT04836780. Registered on 8 April 2021 as EARLY-DEX COVID-19.

Keyphrases

respiratory failure
extracorporeal membrane oxygenation
acute respiratory distress syndrome
mechanical ventilation
coronavirus disease
sars cov
intensive care unit
low dose
liver failure
high dose
hepatitis b virus
drug induced
community acquired pneumonia